
Parents of man who died in Colorado jail say nurses, deputies ignored his pleas for 15 hours
The lawsuit blames them, local government officials and Southern Health Partners for failing to stop the death of Daniel Foard in 2023 by taking him to the hospital. Foard, 32, was a cook at a brewpub and user of fentanyl who was arrested for failing to appear in court. After being segregated and monitored for withdrawal from the synthetic opioid, he began vomiting and complained of stomach pain after being put in a regular jail cell, it said.
The lawsuit alleges Southern Health Partners — the Tennessee-based company they contracted with to provide health care at the La Plata County jail — has tried to maximize its profits at the jail by only having one nurse on duty at a time, leaving it to medically untrained deputies to monitor sick inmates. The company holds hundred of contracts at jails around the country and the lawsuit alleges that is has been involved in lawsuits related to the deaths of at least five other jail inmates nationally.
The company's lawyer, Shira Crittendon, said she had not seen the lawsuit and declined to comment on it.
The sheriff's office referred questions about the the lawsuit to a county spokesperson. In a statement, the county said it had not analyzed the allegations in the lawsuit and does not comment publicly on active litigation.
Autopsy found Foard died because of an ulcer
Foard was found dead in the jail on Aug. 17, 2023, six days after he was arrested.
An autopsy found Foard died as a result of a hole created by an ulcer in his small intestine, which caused inflammation of the tissue lining his abdomen. Such ulcers can let food and digestive juices leak out of the body's digestive tract.
Fentanyl, a synthetic opioid, was found in Foard's blood but the autopsy report did not name that as a cause of his death. Dr. Michael Arnall ruled Foard's death was due to natural causes.
On Aug. 15, 2023, even though Foard had collapsed several times and had trouble standing, he was moved out of an area where he could be more easily observed for problems with his withdrawal and put into a regular jail cell, staggering as we went, the lawsuit said. The day nurse ignored a deputy's concern that he was very unstable, according to the lawsuit brought by lawyers Dan Weiss, Anna Holland Edwards, John Holland and Erica Grossman.
After a deputy delivering breakfast on Aug. 16, 2023 saw that Foard repeatedly fell while trying to get his tray, the jail's day nurse came to check on him, it said. She recorded that Foard reported he had sharp, shooting pain that was a '10' on a scale of one to 10, but she did not call for a doctor or send him to the hospital, it said.
The nurse moved Foard to an empty cell where he could be monitored but didn't tell deputies what he was being monitored for and didn't order any follow up care or check on him, it said. He vomited all day and was moved to another cell and then a third because they had all become so messy with vomit, it said. Surveillance video showed him crawling to the final cell, where it said he continuously called out for help and yelled that he needed to go to a hospital, saying he was vomiting blood. The lawsuit claims that no one responded to his pleas but one deputy could be heard on surveillance video telling him to 'try to hit that drain' with his vomit to keep the cell from becoming dirty.
Another nurse, working the evening shift, only walked by his cell and glanced inside, but did not assess him or provide care as he was pleading for help, the lawsuit said. When she did enter his cell around 10 p.m., Foard was dead, it said. She told state investigators that vomiting was normal for people withdrawing from fentanyl.
State authorities investigated Foard's death
The day shift nurse later told a state investigator that it was not unusual that Foard would not have had his vital signs checked for 12 hours because of the number of inmates the jail's nurses need to provide care, according to a report from an investigation by the Colorado Bureau of Investigations. She also said she didn't think there was anything different she could have done based on Foard's symptoms.
The bureau's findings were forwarded to the 6th District Attorney's Office, which would decide whether any criminal charges were warranted in connection with Foard's death. It's not known whether the office decided to pursue any charges. A telephone message and email sent to District Attorney Sean Murray were not immediately returned.
In a statement, Jim Foard and Susan Gizinski said they want everyone to know about their son's ordeal both to hold those they say are responsible for his death accountable and to change how inmates are treated at the jail.
'Just basic training in having compassion for others would be a great start. But adding more staff is critical too,' they said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Hims & Hers Health Inc (HIMS) Q2 2025 Earnings Call Highlights: Robust Revenue Growth Amid ...
Revenue: $545 million, a 73% year-over-year increase. Adjusted EBITDA Margin: Over 15%. Subscribers: Increased by 73,000 quarter over quarter to over 2.4 million, a 31% year-over-year growth rate. Monthly Average Revenue per Subscriber: Declined quarter over quarter to $74 from $84. Gross Margin: Expanded 3 points quarter over quarter to 76%. Cash and Short-term Investments: Over $1.1 billion at the end of the second quarter. Free Cash Flow: Negative $69 million for the second quarter. Third Quarter Revenue Guidance: Expected between $570 million to $590 million. Full Year Revenue Guidance: Expected between $2.3 billion and $2.4 billion. Full Year Adjusted EBITDA Guidance: Expected between $295 million to $335 million. Warning! GuruFocus has detected 5 Warning Sign with HIMS. Release Date: August 04, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Hims & Hers Health Inc (NYSE:HIMS) reported a 73% year-over-year revenue growth to $545 million in Q2 2025, with an adjusted EBITDA margin exceeding 15%. The company is expanding its platform with new specialties, including hormonal health, which is expected to address significant health issues for both men and women. Hims & Hers Health Inc (NYSE:HIMS) successfully acquired ZAVA, enhancing its presence in the UK and establishing a foundation for further expansion in Europe and Canada. The company is investing in AI and technology to enhance personalized care, aiming to provide 24/7 support and improve patient engagement. Hims & Hers Health Inc (NYSE:HIMS) plans to offer lab testing as a standalone service, which is expected to empower customers with better health insights and proactive health management. Negative Points The company faced headwinds from off-boarding GLP-1 subscribers on commercially available dosages, impacting revenue recognition. There is a decline in the on-demand sexual health subscriber base, which is expected to continue affecting revenue in the short term. Hims & Hers Health Inc (NYSE:HIMS) reported a negative free cash flow of $69 million in Q2 2025 due to significant investments in inventory and working capital. The transition towards more premium daily offerings in the sexual health segment is causing temporary revenue declines. The company anticipates increased marketing and technology investments, which may pressure margins in the near term. Q & A Highlights Q: Why was now the right time to expand internationally, and what made ZAVA the right company to acquire? A: Andrew Dudum, CEO, explained that the acquisition of ZAVA is a strategic move to replicate Hims & Hers' personalized, high-touch, affordable precision medicine model in key international markets. ZAVA's ability to scale in unique regulatory environments was a key factor in the acquisition. The international market is seen as a focused effort, with a multibillion-dollar revenue opportunity in a few key markets. Q: How does the launch of at-home lab testing improve the business and support the broader mission of Hims & Hers? A: Andrew Dudum, CEO, emphasized that at-home lab testing is foundational for transitioning healthcare from treatment to prevention. It simplifies necessary tests, makes them affordable, and educates patients on optimal health metrics. This initiative is expected to open membership opportunities similar to Amazon or Costco, focusing on preventative health. Q: Can you provide insights into the core business dynamics and expectations for Q3, especially regarding the personalized GLP-1 offering? A: Oluyemi Okupe, CFO, noted material headwinds in the GLP-1 segment due to off-boarding commercially available dosages. The core business is experiencing a drag from the sexual health on-demand segment, but specialties like dermatology and weight loss are growing robustly. The transition to daily offerings in sexual health is expected to improve retention and customer lifetime value. Q: What are the expectations for the Canadian expansion and the impact of generic semaglutide pricing? A: Andrew Dudum, CEO, stated that the Canadian expansion will leverage ZAVA's expertise, with offerings under the Hims & Hers brand. The generic semaglutide is expected to be priced significantly lower than branded options, unlocking substantial market access in Canada, where a large portion of the population is affected by weight issues. Q: How is the Hers business performing, and what are the key growth drivers? A: Oluyemi Okupe, CFO, reported robust growth in the Hers business, driven by dermatology, weight loss, and mental health offerings. The upcoming launch of hormonal support for menopause is expected to further catalyze growth. Q: What is the approach to AI investments, and what impact is expected on the business? A: Andrew Dudum, CEO, highlighted a strategy focused on immediate, tactical improvements through AI. The platform's extensive patient interactions allow for rapid deployment of AI use cases, aiming to enhance efficiency and engagement across the provider, patient, and pharmacist interfaces within 3 to 6 months. Q: Can you discuss the marketing strategy and patient acquisition costs for the second half of the year? A: Oluyemi Okupe, CFO, stated that marketing investments will be robust but adhere to a capital allocation framework with a payback period of less than a year. The focus will be on specialty-specific investments and talent acquisition to support new specialties and international expansion. Q: What are the expectations for inventory levels and supply chain management? A: Oluyemi Okupe, CFO, explained that inventory levels increased to ensure a durable supply for new specialties and to leverage the strong balance sheet amid global uncertainties. This is seen as an anomaly, with future inventory adjustments expected to stabilize. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Taking This Supplement Daily Could Add 5 Years to Your Life, Biochemist Says
Taking This Supplement Daily Could Add 5 Years to Your Life, Biochemist Says originally appeared on Men's Fitness. Longevity is a trending topic these days, with people turning to all kinds of products and gimmicks to try and extend their lifespan. But Biochemist Rhonda Patrick just revealed a simple, science-backed solution that could add five years to your life: omega-3's. Omega-3s are fatty acids that play a key role in brain function, heart health, and reducing inflammation throughout the body. They're found primarily in fatty fish like salmon and mackerel, and can be supplemented with fish oil and certain plant sources like flaxseed. An optimal omega-3 index is around 8 percent, but the U.S. average hovers below 5 percent. That difference could translate to a five-year increase in life expectancy."Studies have been done and it takes about on average 2 grams of omega-3 supplementation a day to go from 4 percent to 8 percent," Patrick says. "People that have the 8 percent omega-3 index have a five year increased life expectancy compared to people that have 4 percent." To raise your omega-3 index, consider supplementing with high-quality fish oil or eating fatty fish like salmon regularly. The benefits don't stop there. High omega-3 intake is also associated with better brain health, lower inflammation, reduced risk of Alzheimer's, and even protection against muscle loss. "There's studies showing that you're much less likely to get Alzheimer's disease if you have a high omega-3 index. The quality of life is better," Patrick says. One study even found that smokers with high omega-3 levels live as long as non-smokers with low omega-3 levels. "I think omega-3 has the pharmacological potential to act like drugs but the safety profile of a nutrient," Patrick This Supplement Daily Could Add 5 Years to Your Life, Biochemist Says first appeared on Men's Fitness on Jul 10, 2025 This story was originally reported by Men's Fitness on Jul 10, 2025, where it first appeared. Solve the daily Crossword
Yahoo
2 hours ago
- Yahoo
Cardiologist Swears by 3 Everyday Supplements to Prevent One Deadly Disease
Cardiologist Swears by 3 Everyday Supplements to Prevent One Deadly Disease originally appeared on Men's Fitness. Heart disease is the leading cause of death in the U.S., but certain supplements—paired with a healthy, balanced lifestyle—can help support long-term heart health, as one cardiologist shared. Dmitry Yaranov, M.D., director of the advanced heart failure program at Baptist Memorial Hospital, shared with Business Insider the three daily supplements he swears by to support his heart health. According to the CDC, 919,032 Americans died from cardiovascular disease in 2023, accounting for roughly one in every three deaths. With stats like that, Yaranov is extra mindful of his health. Here are the three supplements he endorses to reduce risk of cardiovascular disease:Omega-3 Yaranov says omega-3 has the strongest research backing for heart health, which is why he's taken it for years. Omega-3 fatty acids—particularly EPA and DHA—help lower triglycerides, reduce blood pressure, and decrease inflammation, all of which are risk factors for cardiovascular disease. It's found naturally in fatty fish like salmon, sardines, and mackerel. But Yaranov admits he doesn't eat enough of it: "I know that for sure, I'm not getting enough fresh, fatty fish in my diet," he said—so the supplements to close the gap. Magnesium Glycinate Reportedly, roughly 50 percent of Americans consume less than the Estimated Average Requirement for magnesium—making a strong case for supplementation. Low magnesium levels are linked to high blood pressure, irregular heart rhythms, and increased risk of heart attack. Magnesium glycinate is more easily absorbed, supporting muscle and nerve function. Vitamin D If you spend most of your time indoors—like Yaranov does—a vitamin D supplement might be necessary. Vitamin D is synthesized when your skin is exposed to sunlight, but modern indoor lifestyles often mean we don't get enough naturally. Vitamin D deficiency could be the risk factor for cardiovascular diseases, such as heart disease and stroke, as one 2023 study Swears by 3 Everyday Supplements to Prevent One Deadly Disease first appeared on Men's Fitness on Jul 18, 2025 This story was originally reported by Men's Fitness on Jul 18, 2025, where it first appeared.